autologous anti-BCMA CAR T cells PHE885

{
  "id": "MLC-T-ONC-011332",
  "term": "autologous anti-BCMA CAR T cells PHE885",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential antineoplastic activity. Upon administration, the autologous anti-BCMA CAR T-cells PHE885 recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.",
  "synonyms": [
    "autologous BCMA-specific CAR T cells PHE885",
    "BCMA-directed autologous CAR-T Cells PHE885"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-bcma-car-t-cells-phe885/"
}